5/23/2016 | PP | Market Commentary: Convertibles mostly quiet; XenoPort surges on takeout news; Allegheny Technologies rises
|
5/23/2016 | CV | Market Commentary: Convertibles mostly quiet; XenoPort surges on takeout news; Allegheny Technologies rises
|
2/3/2015 | CV | XenoPort greenshoe option lifts 2.5% convertible sale to $115 million
|
1/29/2015 | PP | Market Commentary: Yahoo! drops outright, gains on hedge; new XenoPort pops; Performant shares crushed
|
1/29/2015 | CV | Market Commentary: Yahoo! drops outright, gains on hedge; new XenoPort pops; Performant shares crushed
|
1/29/2015 | CV | Market Commentary: Morning Commentary: New XenoPort pops; Performant shares getting crushed; Yahoo! improves on hedge
|
1/29/2015 | CV | New Issue: XenoPort sells $100 million seven-year convertibles at 2.5%, up 22.5%
|
1/28/2015 | PP | Market Commentary: Yahoo! slips on hedge; U.S. Steel gains; XenoPort, Performant Financial offerings on tap
|
1/28/2015 | CV | Market Commentary: Yahoo! slips on hedge; U.S. Steel gains; XenoPort, Performant Financial offerings on tap
|
1/28/2015 | CV | XenoPort plans $100 million seven-year convertibles talked at 2.5% yield, up 22.5%
|
1/24/2014 | PP | XenoPort prices $72 million public stock offering at $6.00 per share
|
1/21/2014 | PP | XenoPort plans to conduct public offering of 10 million common shares
|
11/13/2012 | PP | XenoPort completes $40 million private placement of its common shares
|
7/26/2012 | PP | XenoPort prices $40 million public offering of common shares at $6.50
|
7/25/2012 | PP | XenoPort reports plans to price public offering of its common stock
|
12/31/2008 | PP | New Issue: XenoPort arranges $40 million direct offering of units
|
10/27/2008 | SS | Pictet Funds - Biotech reports 5.13% passive stake in XenoPort
|
2/6/2008 | SP | RBC plans 9% reverse convertibles linked to XenoPort
|
11/15/2006 | BT | XenoPort begins three pivotal phase 3 trials of XP131512 for restless leg syndrome
|
11/6/2006 | BT | XenoPort says resources sufficient to fund operations through mid 2008
|
6/21/2006 | BT | New Issue: XenoPort prices $76.5 million sale of 4.5 million shares at $17.00, discounted from $17.35
|
6/8/2006 | BT | Market Commentary: AtheroGenics drops; Nastech up; Novavax, BioCryst decline; Sirna slides; Acadia off; XenoPort drops
|
6/7/2006 | BT | Market Commentary: Antigenics up 11% on data; Discovery Labs dives 19%; Incyte up; VaxGen slides
|
6/6/2006 | BT | XenoPort plans follow-on offering of 4.5 million shares via Morgan Stanley
|
6/6/2006 | BT | Market Commentary: Xenoport deal emerges; Human Genome up 4%; Anadys, Idenix drop on HGSI news; Onyx up
|
5/4/2006 | BT | XenoPort presents XP13512 data at the American Pain Society meeting
|
3/29/2006 | BT | XenoPort releases positive data from XP13512 'restless leg' trial
|
3/14/2006 | BT | XenoPort starts phase 3 trial of XP13512 for restless legs syndrome
|
1/5/2006 | BT | XenoPort clinical trials prove positive for XP19986, XP13512
|
11/30/2005 | BT | XenoPort, Astellas enter license agreement for XP13512 in Asia
|
11/2/2005 | BT | XenoPort to develop XP21279 for Parkinson's disease, divert resources from migraine treatment
|
10/26/2005 | BT | XenoPort starts phase 2a trial of XP19986 for gastroesophageal reflux disease
|